Accès gratuit
Biologie Aujourd'hui
Volume 210, Numéro 2, 2016
Page(s) 53 - 64
Section L’hypertension artérielle pulmonaire : avancées thérapeutiques
Publié en ligne 30 septembre 2016
  • Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., Rich, S., Barst, R.J., Barrett, P.S., Kral, K.M., Jöbsis, M.M., Loyd, J.E., Murali, S., Frost, A., Girgis, R., Bourge, R.C., Ralph, D.D., Elliott, C.G., Hill, N.S., Langleben, D., Schilz, R.J., McLaughlin, V.V., Robbins, I.M., Groves, B.M., Shapiro, S., and Medsger, T.A. (2000). Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med, 132, 425-434. [CrossRef] [PubMed] [Google Scholar]
  • Barst, R.J., Rubin, L.J., Long, W.A., McGoon, M.D., Rich, S., Badesch, D.B., Groves, B.M., Tapson, V.F., Bourge, R.C., Brundage, B.H., Koerner, S.K., Langleben, D., Keller, C.A., Murali, S., Uretsky, B.F., Clayton, L.M., Jöbsis, M.M., Blackburn, S.D., Shortino, D., and Crow, J.W. (1996). A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. N Engl J Med, 334, 296-301. [CrossRef] [PubMed] [Google Scholar]
  • Channick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F., Badesch, D.B., Roux, S., Rainisio, M., Bodin, F., and Rubin, L.J. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 358, 1119-1123. [CrossRef] [PubMed] [Google Scholar]
  • Fadel, E., Mercier, O., Mussot, S., Leroy-Ladurie, F., Cerrina, J., Chapelier, A., Simonneau, G., and Dartevelle, P. (2010). Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardio-Thorac Surg, 38, 277-284. [CrossRef] [MathSciNet] [Google Scholar]
  • Galiè, N., Manes, A., and Branzi, A. (2004). The endothelin system in pulmonary arterial hypertension. Cardiovasc Res, 61, 227-237. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Badesch, D., Oudiz, R., Simonneau, G., McGoon, M.D., Keogh, A.M., Frost, A.E., Zwicke, D., Naeije, R., Shapiro, S., Olschewski, and H.,Rubin, L.J. (2005a). Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 46, 529-535. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., Simonneau, G., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group, (2005b). Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 353, 2148-2157. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Beghetti, M., Gatzoulis, M.A., Granton, J., Berger, R.M.F., Lauer, A., Chiossi, E., Landzberg, M., Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. (2006). Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 114, 48-54. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., Ghofrani, H.A., Badesch, D.B., McGoon, M.D., McLaughlin, V.V., Roecker, E.B., Gerber, M.J., Dufton, C., Wiens, B.L., Rubin, L.J., Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group, (2008a). Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 117, 3010-3019. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G., Chiossi, E., Kusic-Pajic, A., and Simonneau, G. (2008b). Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet, 371, 2093-2100. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., Safdar, Z., Shapiro, S., White, R.J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R.J., Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. (2009). Tadalafil therapy for pulmonary arterial hypertension. Circulation, 119, 2894-2903. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., and Simonneau, G. (2013). The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol, 62, D1-D3. [CrossRef] [PubMed] [Google Scholar]
  • Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., Ghofrani, A., Gomez Sanchez, M.A., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L.A., Trindade, P.T., Zompatori, M., Hoeper, M. (2015). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J, 46, 903-975. [CrossRef] [PubMed] [Google Scholar]
  • Ghofrani, H.-A., D’Armini, A.M., Grimminger, F., Hoeper, M.M., Jansa, P., Kim, N.H., Mayer, E., Simonneau, G., Wilkins, M.R., Fritsch, A., Neuser, D., Weimann, G., Wang, C., CHEST-1 Study Group. (2013a). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 369, 319-329. [CrossRef] [PubMed] [Google Scholar]
  • Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A.M., Langleben, D., Kilama, M.O., Fritsch, A., Neuser, D., Rubin, L.J., PATENT-1 Study Group (2013b). Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med, 369, 330-340. [CrossRef] [PubMed] [Google Scholar]
  • Giaid, A., Yanagisawa, M., Langleben, D., Michel, R.P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W.P., and Stewart, D.J. (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 328, 1732-1739. [CrossRef] [PubMed] [Google Scholar]
  • Guillevin, L., Armstrong, I., Aldrighetti, R., Howard, L.S., Ryftenius, H., Fischer, A., Lombardi, S., Studer, S., and Ferrari, P. (2013). Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev, 22, 535-542. [CrossRef] [PubMed] [Google Scholar]
  • Higenbottam, T., Butt, A.Y., McMahon, A., Westerbeck, R., and Sharples, L. (1998). Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart Br Card Soc, 80, 151-155. [Google Scholar]
  • Hoeper, M.M., Pletz, M.W., Golpon, H., and Welte, T. (2007). Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J, 29, 944-950. [CrossRef] [PubMed] [Google Scholar]
  • Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T., Torres, F., Wilkins, M.R., and Badesch, D.B. (2013). Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol, 62, D42-50. [CrossRef] [PubMed] [Google Scholar]
  • Humbert, M., Maître, S., Capron, F., Rain, B., Musset, D., and Simonneau, G. (1998). Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med, 157, 1681-1685. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Humbert, M., Barst, R.J., Robbins, I.M., Channick, R.N., Galiè, N., Boonstra, A., Rubin, L.J., Horn, E.M., Manes, A., and Simonneau, G. (2004). Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 24, 353-359. [CrossRef] [PubMed] [Google Scholar]
  • Humbert, M., Segal, E.S., Kiely, D.G., Carlsen, J., Schwierin, B., and Hoeper, M.M. (2007). Results of European post-marketing. Surveillance of bosentan in pulmonary hypertension. Eur Respir J, 30, 338-344. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Iversen, K., Jensen, A.S., Jensen, T.V., Vejlstrup, N.G., and Søndergaard, L. (2010). Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J, 31, 1124-1131. [CrossRef] [PubMed] [Google Scholar]
  • Jenkins, D., Mayer, E., Screaton, N., and Madani, M. (2012). State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management. Eur Respir Rev, 21, 32-39. [CrossRef] [PubMed] [Google Scholar]
  • Jones, D.A., Benjamin, C.W., and Linseman, D.A. (1995). Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol, 48, 890-896. [PubMed] [Google Scholar]
  • Kovacs, G., Berghold, A., Scheidl, S., and Olschewski, H. (2009). Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J, 34, 888-894. [CrossRef] [PubMed] [Google Scholar]
  • Lang, I.M., Pesavento, R., Bonderman, D., and Yuan, J.X.-J. (2013). Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J, 41, 462-468. [CrossRef] [PubMed] [Google Scholar]
  • Lang, R.M., Badano, L.P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F.A., Foster, E., Goldstein, S.A., Kuznetsova, T., Lancellotti, P., Muraru, D., Picard, M.H., Rietzschel, E.R., Rudski, L., Spencer, K.T., Tsang, W., and Voigt, J.-U. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 16, 233-270. [CrossRef] [PubMed] [Google Scholar]
  • Madani, M.M., Auger, W.R., Pretorius, V., Sakakibara, N., Kerr, K.M., Kim, N.H., Fedullo, P.F., and Jamieson, S.W. (2012). Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg, 94, 97-103; discussion 103. [CrossRef] [PubMed] [Google Scholar]
  • Mayer, E., Jenkins, D., Lindner, J., D’Armini, A., Kloek, J., Meyns, B., Ilkjaer, L.B., Klepetko, W., Delcroix, M., Lang, I., Pepke-Zaba, J., Simonneau, G., and Dartevelle, P. (2011). Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg, 141, 702-710. [CrossRef] [PubMed] [Google Scholar]
  • McLaughlin, V.V., Gaine, S.P., Howard, L.S., Leuchte, H.H., Mathier, M.A., Mehta, S., Palazzini, M., Park, M.H., Tapson, V.F., and Sitbon, O. (2013). Treatment goals of pulmonary hypertension. J Am Coll Cardiol, 62, D73-81. [CrossRef] [PubMed] [Google Scholar]
  • Mereles, D., Ehlken, N., Kreuscher, S., Ghofrani, S., Hoeper, M.M., Halank, M., Meyer, F.J., Karger, G., Buss, J., Juenger, J., Holzapfel, N., Opitz, C., Winkler, J., Herth, F.F.J., Wilkens, H., Katus, H.A., Olschewski, H., and Grünig, E. (2006). Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation, 114, 1482-1489. [CrossRef] [PubMed] [Google Scholar]
  • Montani, D., Jaïs, X., Price, L.C., Achouh, L., Degano, B., Mercier, O., Mussot, S., Fadel, E., Dartevelle, P., Sitbon, O., Simonneau, G., and Humbert, M. (2009a). Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J, 34, 1348-1356. [CrossRef] [PubMed] [Google Scholar]
  • Montani, D., Price, L.C., Dorfmuller, P., Achouh, L., Jaïs, X., Yaïci, A., Sitbon, O., Musset, D., Simonneau, G., and Humbert, M. (2009b). Pulmonary veno-occlusive disease. Eur Respir J, 33, 189-200. [CrossRef] [PubMed] [Google Scholar]
  • Montani, D., Savale, L., Natali, D., Jaïs, X., Herve, P., Garcia, G., Humbert, M., Simonneau, G., and Sitbon, O. (2010). Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J, 31, 1898-1907. [CrossRef] [PubMed] [Google Scholar]
  • Montani, D., Lau, E.M., Dorfmüller, P., Girerd, B., Jaïs, X., Savale, L., Perros, F., Nossent, E., Garcia, G., Parent, F., Fadel, E., Soubrier, F., Sitbon, O., Simonneau, G., and Humbert, M. (2016). Pulmonary veno-occlusive disease. Eur Respir J, (sous presse) DOI:10.1183/13993003.00026-2016 [Google Scholar]
  • Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L.J., Nikkho, S., Speich, R., Hoeper, M.M., Behr, J., Winkler, J., Sitbon, O., Popov, W., Ghofrani, H.A., Manes, A., Kiely, D.G., Ewert, R., Meyer, A., Corris, P.A., Delcroix, M., Gomez-Sanchez, M., Siedentop, H., Seeger, W., Aerosolized Iloprost Randomized Study Group. (2002). Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 347, 322-329. [CrossRef] [PubMed] [Google Scholar]
  • Perrot de, M., Granton, J.T., McRae, K., Pierre, A.F., Singer, L.G., Waddell, T.K., and Keshavjee, S. (2012). Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. J Thorac Cardiovasc Surg, 143, 910-918. [CrossRef] [PubMed] [Google Scholar]
  • Pulido, T., Adzerikho, I., Channick, R.N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., Mittelholzer, C.M., Perchenet, L., Sastry, B.K.S., Sitbon, O., Souza, R., Torbicki, A., Zeng, X., Rubin, L.J., Simonneau, G., SERAPHIN Investigators. (2013). Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 369, 809-818. [CrossRef] [PubMed] [Google Scholar]
  • Rich, S., Dantzker, D.R., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., Detre, K.M., Fishman, A.P., Goldring, R.M., Groves, B.M., and Koerner, S.K. (1987). Primary pulmonary hypertension. A national prospective study. Ann Intern Med, 107, 216-223. [CrossRef] [PubMed] [Google Scholar]
  • Rich, S., Kaufmann, E., and Levy, P.S. (1992). The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 327, 76-81. [CrossRef] [PubMed] [Google Scholar]
  • Rich, J.D., Thenappan, T., Freed, B., Patel, A.R., Thisted, R.A., Childers, R., and Archer, S.L. (2013). QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol, 167, 669-676. [CrossRef] [PubMed] [Google Scholar]
  • Rubin, L.J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W.B., Diehl, J.H., Crow, J., and Long, W. (1990). Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med, 112, 485-491. [CrossRef] [PubMed] [Google Scholar]
  • Rubin, L.J., Badesch, D.B., Barst, R.J., Galiè, N., Black, C.M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., Landzberg, M., and Simonneau, G. (2002). Bosentan Therapy for Pulmonary Arterial Hypertension. N Engl J Med, 346, 896-903. [CrossRef] [PubMed] [Google Scholar]
  • Sastry, B.K.S., Narasimhan, C., Reddy, N.K., and Raju, B.S. (2004). Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol, 43, 1149-1153. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Shen, Y., Wan, C., Tian, P., Wu, Y., Li, X., Yang, T., An, J., Wang, T., Chen, L., and Wen, F. (2014). CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. Medicine (Baltimore), 93, e256. [CrossRef] [PubMed] [Google Scholar]
  • Simonneau, G., Barst, R.J., Galiè, N., Naeije, R., Rich, S., Bourge, R.C., Keogh, A., Oudiz, R., Frost, A., Blackburn, S.D., Crow, J.W., Rubin, L.J., Treprostinil Study Group. (2002). Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 165, 800-804. [Google Scholar]
  • Simonneau, G., Torbicki, A., Hoeper, M.M., Delcroix, M., Karlócai, K., Galiè, N., Degano, B., Bonderman, D., Kurzyna, M., Efficace, M., Giorgino, and R.,Lang, I.M. (2012). Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J, 40, 874-880. [CrossRef] [PubMed] [Google Scholar]
  • Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M.A., Krishna Kumar, R., Landzberg, M., Machado, R.F., Olschewski, H., Robbins, I.M., and Souza, R. (2013). Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 62, D34-41. [CrossRef] [PubMed] [Google Scholar]
  • Singh, T.P., Rohit, M., Grover, A., Malhotra, S., and Vijayvergiya, R. (2006). A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J, 151, 851.e1-5. [CrossRef] [Google Scholar]
  • Sitbon, O., Channick, R., Chin, K.M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M.M., Lang, I.M., Preiss, R., Rubin, L.J., Di Scala, L., Tapson, V., Adzerikho, I., Liu, J., Moiseeva, O., Zeng, X., Simonneau, G., McLaughlin, V.V., Williams, P.G., Beghetti, M., Corris, P., Pepke-Zaba, J., Souza, R., DeMets, D.L., Gomberg-Maitland, M., Greenberg, B.H., Schulman, S., Douketis, J., GRIPHON Investigators. (2015). Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med, 373, 2522-2533. [CrossRef] [PubMed] [Google Scholar]
  • Sitbon, O., Sattler, C., Bertoletti, L., Savale, L., Cottin, V., Jaïs, X., De Groote, P., Chaouat, A., Chabannes, C., Bergot, E., Bouvaist, H., Dauphin, C., Bourdin, A., Bauer, F., Montani, D., Humbert, M., and Simonneau, G. (2016). Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J, 47, 1727-1736. [CrossRef] [PubMed] [Google Scholar]
  • Sun, P.-Y., Jiang, X., Gomberg-Maitland, M., Zhao, Q.-H., He, J., Yuan, P., Zhang, R., and Jing, Z.-C. (2012). Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest, 141, 374-380. [CrossRef] [PubMed] [Google Scholar]
  • Sun, X.-G., Hansen, J.E., Oudiz, R.J., and Wasserman, K. (2003). Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol, 41, 1028-1035. [CrossRef] [PubMed] [Google Scholar]
  • Tan, R.T., Kuzo, R., Goodman, L.R., Siegel, R., Haasler, G.B., and Presberg, K.W. (1998). Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest, 113, 1250-1256. [CrossRef] [PubMed] [Google Scholar]
  • Tantini, B., Manes, A., Fiumana, E., Pignatti, C., Guarnieri, C., Zannoli, R., Branzi, A., and Galiè, N. (2005). Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol, 100, 131-138. [CrossRef] [PubMed] [Google Scholar]
  • Toyoda, Y., Thacker, J., Santos, R., Nguyen, D., Bhama, J., Bermudez, C., Kormos, R., Johnson, B., Crespo, M., Pilewski, J., Teuteberg, J., Alvarez, R., Mathier, M., McNamara, D., McCurry, K., Zenati, M., and Hattler, B. (2008). Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg, 86, 1116-1122. [CrossRef] [PubMed] [Google Scholar]
  • Trip, P., Nossent, E.J., de Man, F.S., van den Berk, I.A.H., Boonstra, A., Groepenhoff, H., Leter, E.M., Westerhof, N., Grünberg, K., Bogaard, H.-J., and Vonk-Noordegraaf, A. (2013). Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J, 42, 1575-1585. [CrossRef] [PubMed] [Google Scholar]
  • Trulock, E.P., Christie, J.D., Edwards, L.B., Boucek, M.M., Aurora, P., Taylor, D.O., Dobbels, F., Rahmel, A.O., Keck, B.M., Hertz, M.I. (2007). Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant, 26, 782-795. [CrossRef] [PubMed] [Google Scholar]
  • Tunariu, N., Gibbs, S.J.R., Win, Z., Gin-Sing, W., Graham, A., Gishen, P., and Al-Nahhas, A. (2007). Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med, 48, 680-684. [CrossRef] [PubMed] [Google Scholar]
  • Wharton, J., Strange, J.W., Møller, G.M.O., Growcott, E.J., Ren, X., Franklyn, A.P., Phillips, S.C., and Wilkins, M.R. (2005). Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med, 172, 105-113. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.